Successful parenteral desensitization to paclitaxel.

BACKGROUND Paclitaxel, a member of a new class of antineoplastic agents called the taxanes, has been associated with anaphylactoid reactions. OBJECTIVE We report a case of successful parental desensitization to paclitaxel. METHODS Desensitization was performed with serial 10-fold dilutions (up to 1:100,000) of paclitaxel in sufficient volume to administer successive doses of 1, 2, 4, and 8 ml. Basophil histamine release tests were performed with paclitaxel alone, vehicle alone, and paclitaxel and vehicle combined to determine which agent was responsible for the anaphylactoid reactions. RESULTS After parental desensitization was performed, the patient was able to tolerate infusion of paclitaxel without complications or need for antihistamines or steroids. Basophil histamine release occurred only with paclitaxel and not with the vehicle. CONCLUSIONS Successful parenteral desensitization to paclitaxel can be achieved; it is paclitaxel, and not its vehicle, that is most likely responsible for anaphylactoid reactions in patients undergoing treatment.

[1]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Kagey‐Sobotka,et al.  Hyperosmolar triggering of histamine release from human basophils. , 1981, The Journal of clinical investigation.

[3]  N. Rose,et al.  Manual of clinical immunology , 1976 .

[4]  K. Lucchesi,et al.  Paclitaxel rechallenge failure after a major hypersensitivity reaction. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Griffith,et al.  Anaphylactoid Reactions Associated with Parenteral Cyclosporine Use: Possible Role of Cremophor EL , 1985, Drug intelligence & clinical pharmacy.

[6]  H. Spencer,et al.  Biological studies on stable and radioactive rare earth compounds. III. Distribution of radioactive yttrium in normal and ascites-tumor-bearing mice, and in cancer patients with serous effusions. , 1954, Journal of the National Cancer Institute.

[7]  H. Hertz,et al.  VM‐26 (Teniposide)-Induced Hypersensitivity and Degranulation of Basophils in Children , 1988, The American journal of pediatric hematology/oncology.

[8]  J. Watkins,et al.  Suspected anaphylactic reaction to Cremophor EL. , 1980, British medical journal.

[9]  M. Dembo,et al.  Antigen-specific desensitization of human basophils. , 1979, Journal of immunology.

[10]  R. Siraganian An automated continuous-flow system for the extraction and fluorometric analysis of histamine. , 1974, Analytical biochemistry.

[11]  L. Lichtenstein,et al.  A controlled trial of immunotherapy in insect hypersensitivity. , 1978, The New England journal of medicine.

[12]  M. Piccart,et al.  Successful re-treatment with taxol after major hypersensitivity reactions. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Middleton,et al.  Allergy, principles and practice , 1978 .

[14]  B. Williams,et al.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. , 1990, Cancer research.

[15]  S. Lippman,et al.  Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.